Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE-A phase 3 trial of lumasiran in primary hyperoxaluria type 1
NL-OMON49328Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Apr 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary Hyperoxaluria Type 1 (PH1) comparing Lumasiran with Placebo (2 arms). Primary endpoint: Percent change in 24-hour urinary oxalate excretion from baseline to Month 6. Started Apr 2019; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NL-OMON49328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49328.